When MorphoSys acquired Cambridge, Massachusetts-based Constellation Pharmaceuticals last year, the $1.7 billion deal value represented the entirety of the cancer drug developer’s pipeline ...

Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, raised $60 million in a downsized offering of 4.0 million shares at $15, the midpoint ...

Four bright stars outline the package, while three others make up the decorative bow. [Stunning Night Sky Photos of December 2012] ... within the faint zodiacal constellation of Cancer. ...

MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the ...

Constellation Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 PROSTAR Combination Study of CPI-1205 in Advanced Form of Prostate Cancer First solid tumor study from company’s EZH2 ...

Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise ...

Cancer is a humble constellation, nestled in between its louder neighbours Gemini and Leo. Without any particularly bright stars of its own, Cancer is the faintest of all the zodiacal ...

In the sky, the constellation of Cancer is practically an empty space in the sky, positioned between the Twin Stars (Pollux and Castor) of Gemini and the Sickle of Leo.

CHICAGO, IL, Sept. 2, 2015 - Constellation Brands, Inc. (NYSE:STZ and STZ.B), a leading beverage alcohol company, recently presented a check in the amount of $1,000,000 to The V Foundation for ...